Icell Gene Therapeutics
Clinical trials sponsored by Icell Gene Therapeutics, explained in plain language.
-
Engineered immune cells take aim at Hard-to-Treat muscle disease
Disease control Recruiting nowThis phase 1 trial tests a new cell therapy called ICG318 CAR-T in adults with refractory inflammatory myopathy, a condition where the immune system attacks muscles, causing weakness and inflammation. The therapy uses a patient's own immune cells, engineered to target specific ma…
Phase: PHASE1 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Engineered immune cells take on tough leukemia in early trial
Disease control Recruiting nowThis early-stage trial tests a new treatment called ICG415 CAR-T cells for adults with acute myeloid leukemia that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, engineering them to recognize and attack leukemia cel…
Phase: PHASE1 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Experimental CAR t therapy targets two cancers at once
Disease control Recruiting nowThis early-stage trial is testing a new type of immune cell therapy called BCMA-CD19 cCAR T cells in 12 patients with multiple myeloma or plasmacytoid lymphoma that has come back or not responded to standard treatments. The therapy uses a patient's own modified immune cells to at…
Phase: PHASE1 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 18:30 UTC